Plozalizumab

Plozalizumab
Monoclonal antibody
TypeWhole antibody
SourceHumanized (from mouse)
TargetCCR2
Clinical data
Other nameshu1D9
ATC code
  • none
Identifiers
CAS Number
ChemSpider
  • none
UNII
KEGG
Chemical and physical data
FormulaC6490H10052N1736O2018S42
Molar mass146032.46 g·mol−1

Plozalizumab (INN; hu1D9) is a humanized monoclonal antibody designed for the treatment of diabetic nephropathy and arteriovenous graft patency.[1][2]

This drug was developed by Takeda Pharmaceuticals International Co.

References

  1. Statement On A Nonproprietary Name Adopted By The USAN Council - Plozalizumab, American Medical Association.
  2. World Health Organization (2015). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 113" (PDF). WHO Drug Information. 29 (2).
This article is issued from Offline. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.